Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

66.70
-0.9800-1.45%
Post-market: 66.41-0.2900-0.43%19:30 EDT
Volume:1.59M
Turnover:106.77M
Market Cap:12.89B
PE:176.00
High:68.34
Open:67.55
Low:66.52
Close:67.68
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.90
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.04
PE(LYR):37.06

Loading ...

U.S. RESEARCH ROUNDUP-CrowdStrike, Oracle, Vulcan Materials

Reuters
·
Mar 04

Amicus Therapeutics Inc. Held Special Stockholder Meeting

Reuters
·
Mar 04

Cantor Fitzgerald Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Mar 02

H.C. Wainwright Remains a Hold on BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Mar 02

BioMarin Pharmaceutical Price Target Maintained With a $55.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 02

BioMarin Says US FDA Approves Application for Rare Metabolic Disorder Treatment in Adolescents

MT Newswires Live
·
Mar 02

BioMarin announces U.S FDA approved sBLA for Palynziq

TIPRANKS
·
Mar 02

BRIEF-U.S. Food And Drug Administration Approves Biomarin's Palynziq® (Pegvaliase-Pqpz) For Adolescents 12 Years Of Age And Older With Phenylketonuria (Pku)

Reuters
·
Feb 28

FDA approves BioMarin PALYNZIQ for adolescents 12 and older with PKU

Reuters
·
Feb 28

Ascendis wins U.S. approval for therapy for children with dwarfism

Reuters
·
Feb 28

BioMarin EVP and Chief Legal Officer George Eric Davis Disposes of Common Shares

Reuters
·
Feb 27

BioMarin Pharmaceutical Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Feb 27

These Analysts Revise Their Forecasts On BioMarin Pharmaceutical After Q4 Results

Benzinga_recent_news
·
Feb 26

BioMarin Pharmaceutical Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
Feb 25

BioMarin price target lowered to $86 from $106 at Guggenheim

TIPRANKS
·
Feb 25

Barclays Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25

Stock Track | BioMarin Pharmaceutical Soars 5.30% Intraday on Positive Analyst Ratings and Upcoming Investor Conferences

Stock Track
·
Feb 24

Stock Track | Biomarin Pharmaceutical Plummets 5.15% in Pre-Market After Oppenheimer Cuts Price Target

Stock Track
·
Feb 24

Stock Track | Biomarin Pharmaceutical Plunges 5.09% in Pre-Market After Oppenheimer Cuts Target Price

Stock Track
·
Feb 24